, headquartered in Taiwan for 17 years, is dedicated to the development of genetic detection platform, incorporated with Microarrays, Next Generation Sequencing (NGS) and Big Data analysis for health informatics, positioning as the only microarray developer in Asia. The core services of Phalanx Biotech lie upon five areas within Reproductive Medicine
(prenatal/postnatal testing), Population Medicine, Medical Oncology, Liver Cancer ctDNA Methylation Test
, and scientific research services.
- Reproductive Medicine - Phalanx Biotech self-developed the product of chromosomal microarray-"CytoOneArray", which can identify chromosomal aneuploidy and other large changes in the structure of chromosomes in prenatal and postnatal testing. CytoOneArray is capable of detecting more than +400 diseases per test, effectively for Developmental Delay (DD) and Intellectual Disability (ID). It provides advanced genetic diagnostic tools for obstetricians and pediatricians.
- Liver Cancer ctDNA Methylation Test - A breakthrough genetic testing development by leveraging ctDNA methylation markers for early liver cancer detection and screening.
- Population Medicine - Risk and predisposition assessment for obesity, 13 chronic diseases & 17 cancers. Additionally providing custom arrays for SNP genotyping and custom-designed services for consumer genetic testing.
- Medical Oncology - Provides genetic tests for new generation cancer medications for the treatment tailored to each patient.